It is generally accepted that an important mechanism by which hypertriglyceridaemia is associated with low levels of HDLcholesterol, is an increased transfer of cholesteryl esters from HDL to apo-B containing lipoproteins [1] . In a recent report, Passarelli et al. [2] describe how in vitro glycation of lipoproteins can accelerate this process. As HbA 1 c is the index of glycation in vivo, if this mechanism is operational in vivo, an inverse association between HDL-cholesterol concentrations and HbA 1 c would be expected. No data had, however, been published previously. To investigate this issue we analysed the HbA 1 c and HDL-cholesterol data in The Hoorn Study, a large population study on glucose tolerance in an elderly Caucasian population [3] . We analysed subjects separately classified as having normal glucose tolerance (NGT), impaired glucose tolerance (IGT) and newly diagnosed Type II (non-insulin-dependent) diabetes mellitus. Subjects known to have diabetes and those who were treated with lipid-lowering drugs were excluded. NGT was esthablished in 1986 subjects (1053 women) aged 60.9 ± 7.2 years (mean ± SD), and with fasting glucose 5.4 ± 0.5 mmol/l, HbA 1 c 5.3 ± 0.5 %, HDL 1.35 ± 0.37 mmol/l and fasting triglycerides 1.48 ± 0.75 mmol/l. IGT was found in 244 subjects (144 women) aged 64.6 ± 7.4 years, and with fasting glucose 5.9 ± 0.7 mmol/l, HbA 1 c 5.5 ± 0.5 %, HDL 1.25 ± 0.34 mmol/l and fasting triglycerides 1.96 ± 1.17 mmol/l. Type II diabetes was diagnosed in 117 subjects (62 women) aged 65.7 ± 6.7 years, and with fasting glucose 8.3 ± 3.2 mmol/l, HbA 1 c 6.7 ± 1.8 %, HDL 1.17 ± 0.33 mmol/l and fasting triglycerides 2.37 ± 1.58 mmol/l. Three different linear regression analyses models were used. First the association between HbA 1 c (independent variable) and HDL-cholesterol (dependent variable) was adjusted for age and sex alone (Model 1). Then additional adjustment for fasting triglycerides was applied (Model 2). The third model was adjusted additionally for waist-to-hip ratio, BMI and fasting insulin concentrations (Model 3). The results of the linear regression analyses performed in NGT, IGT and Type II diabetic subjects are shown in Table 1 . These show that an association between HDL-cholesterol and HbA 1c exists in all three subgroups, though stronger in NGT subjects than in subjects with IGT and Type II diabetes. In this respect it should be noted that the number of subjects in the IGT and Type II diabetic groups are relatively small. An important part of the association between HbA 1 c and HDL-cholesterol disappears after adjustment for fasting triglycerides in all subgroups. As within the insulin resistance syndrome disturbances of lipid and glucose metabolism coincide [1], we investigated whether this syndrome itself could affect the association under investigation, by further adjustments for several hallmarks of this syndrome, namely BMI, waist-tohip ratio and fasting insulin. These adjustments, however, did not change the association between HbA 1 c and HDL-cholesterol more than adjustment for fasting triglycerides alone. The remaining association between HbA 1c and HDL-cholesDiabetologia (1998) 41: 1249±1252
Letters to the editor Ó Springer-Verlag 1998 Recently, a missense mutation of the amylin gene (S20G) has been described and implicated in the pathogenesis of Type II diabetes, especially early-onset diabetes, in Japanese patients [4] . Since the genetic factors contributing to Type II diabetes can vary among different ethnic groups, we searched for the S20G mutation of the amylin gene and investigated its role in diabetes phenotypes and glucose metabolism, including insulin secretion and insulin sensitivity, in a Taiwanese population. We recruited 99 unrelated normal control subjects, 24 subjects with impaired glucose tolerance (IGT), 122 with Type I diabetes and 182 with Type II diabetes from Chinese people living in Taiwan. The demographic characteristics of the normal control group and the subjects with IGT, Type I and Type II diabetes are listed in Table 1 . Except for the subjects with Type I diabetes they were matched for age, sex, and body mass index. The S20G mutation of the amylin gene (Genbank Accession M26650) was detected by polymerase chain reaction and restriction fragment length polymorphism and then confirmed by DNA sequence analyses [4] . Pedigree members of the subjects with this mutation were studied by oral glucose tolerance tests, glucagon stimulation tests, and insulin suppression tests.
The S20G mutation of the amylin gene was found in four patients with normal glucose tolerance, one with IGT, two with Type I diabetes and three with Type II diabetes (Table 1) .
There was no significant difference in the frequencies of the amylin gene mutation among the subjects with IGT and diabetes as compared with that in the normal control subjects (Table 1, p > 0.05). For the normal subjects with the amylin gene mutation, their ages at recruitment were 51, 55, 55 and 68 years, respectively. For the Type I diabetic subjects found to have the amylin gene mutation, the ages at onset were 6 and 3 years, respectively. Human leukocyte antigen DR genotyping showed that they carried DR3/DR4 and DR4/DR4, respectively. Both cases were positive for IA-2 (ICA512) autoantibody but negative for GAD 65 antibodies. For the Type II diabetic subjects with amylin gene mutation, the ages at onset were 45, 48 and 57 years, respectively. Pedigree studies showed that the S20G mutation of the amylin gene did not co-segregate with the disease, suggesting this mutation was neither sufficient nor necessary for the development of diabetes. We could not find any significant difference in the age at onset, gender, body mass index, waist-hip ratio, systolic and diastolic blood pressures, fasting plasma glucose and insulin levels between the diabetic subjects with and without the amylin gene mutation.
To evaluate the role of the amylin gene mutation on insulin secretion, we studied insulin and C-peptide responses after oral glucose and intravenous glucagon stimulation in the nondiabetic pedigree members. Among them, subjects with muta-Corresponding author: Dr. Lee-Ming Chuang, Department of Internal Medicine, National Taiwan University Hospital, 7, Chung-Shan South Road, Taipei, Taiwan 2 ) 24.2 ± 3.4 25.1 ± 2.8 19.0 ± 2.8 25.1 ± 3.9 Age at onset (years) ± ± 9 ± 6 4 8±12
Cases (%) with mutation 4 (4.4 %) 1 (4.2 %) 2 (1.6 %) 3 (1.6 %)
95 % Confidence interval 0.2±7.9 % 3.8±12.2 % 0.6±3.9 % 0.2±3.5 %
